Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...
The Goodman raising, the ASX’s sixth-largest ever and the bourse’s largest real estate deal, was done unsounded and with no ...
Goldman Sachs has appointed insiders William Connolly and Michael Voris as co-heads of Equity Capital Markets (ECM) in the ...
Waystar Holding Corp. (Nasdaq: WAY) ("Waystar"), a provider of leading healthcare payments software, today announced the ...
Loop Capital Markets analyst Jeffrey Stevenson maintained a Hold rating on JELD-WEN (JELD – Research Report) today and set a price target of ...
LONDON (Reuters) - Wall Street stocks could be facing a correction because of ructions in the options market, Goldman Sachs specialist ... will put pressure on stock markets and stoke volatility ...
China stocks are starting to feel the benefits of AI, but Goldman Sachs says there are reasons not to rush in.
Goldman Sachs is poised to benefit from an anticipated resurgence in capital markets activity. Analysts are optimistic about the company's prospects in this core area of its business, with several ...
Goldman Sachs would consider acquisitions in asset and wealth management, but would be highly selective about any deal, CEO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback